The prognostic value of bone marrow retention index and bone marrow-to-liver ratio of baseline 18F-FDG PET/CT in diffuse large B-cell lymphoma
Objective To determine prognostic value of bone marrow retention index (RI-bm) and bone marrow-to-liver ratio (BLR) measured on baseline dual-phase 18F-FDG PET/CT in a series of newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) treated homogeneously with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. Patients and methods This prospective study enrolled 135 patients with newly diagnosed DLBCL. All patients underwent dual-phase 18F-FDG PET/CT. The following PET parameters were calculated for both tumor and bone marrow: maximum standardized uptake value (SUVmax) at both time points (SUVmax early and SUVmax delayed), SUVmax increment (SUVinc), RI, and BLR. Patients were treated with R-CHOP regimen and response at end of treatment was assessed. Results The final analysis included 98 patients with complete remission. At a median follow-up of 22 months, 57 patients showed no relapse, 74 survived, and 24 died. The 2-year relapse-free survival (RFS) values for patients with higher and lower RI-bm were 20% and 65.1%, respectively (p < 0.001), and for patients with higher and lower BLR were 30.2% and 69.6%, respectively (p < 0.001). The 2-year overall survival (OS) values for patients with higher and lower RI-bm were 60% and 76.3%, respectively (p = 0.023), and for patients with higher and lower BLR were 57.3% and 78.6%, respectively (p = 0.035). Univariate analysis revealed that RI-bm and BLR were independent significant prognostic factors for both RFS and OS (hazard ratio [HR] = 4.02, p < 0.001, and HR = 3.23, p < 0.001, respectively) and (HR = 2.83, p = 0.030 and HR = 2.38, p = 0.041, respectively). Conclusion Baseline RI-bm and BLR were strong independent prognostic factors in DLBCL patients. Clinical relevance statement Bone marrow retention index (RI-bm) and bone marrow-to-liver ratio (BLR) could represent suitable and noninvasive positron emission tomography/computed tomography (PET/CT) parameters for predicting pretreatment risk in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. Key Points • Bone marrow retention index (RI-bm) and bone marrow-to-liver ratio (BLR) are powerful prognostic variables in diffuse large B-cell lymphoma (DLBCL) patients. • High BLR and RI-bm are significantly associated with poor overall survival (OS) and relapse-free survival (RFS). • RI-bm and BLR represent suitable and noninvasive risk indicators in DLBCL patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
European radiology - 34(2023), 4 vom: 09. Okt., Seite 2500-2511 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
El-Azony, Ahmed [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Fluorodeoxyglucose F18 |
| Anmerkungen: |
© The Author(s), under exclusive licence to European Society of Radiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00330-023-10150-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055234682 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055234682 | ||
| 003 | DE-627 | ||
| 005 | 20240322064643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00330-023-10150-z |2 doi | |
| 035 | |a (DE-627)SPR055234682 | ||
| 035 | |a (SPR)s00330-023-10150-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.64 |2 bkl | ||
| 100 | 1 | |a El-Azony, Ahmed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a The prognostic value of bone marrow retention index and bone marrow-to-liver ratio of baseline 18F-FDG PET/CT in diffuse large B-cell lymphoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to European Society of Radiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Objective To determine prognostic value of bone marrow retention index (RI-bm) and bone marrow-to-liver ratio (BLR) measured on baseline dual-phase 18F-FDG PET/CT in a series of newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) treated homogeneously with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. Patients and methods This prospective study enrolled 135 patients with newly diagnosed DLBCL. All patients underwent dual-phase 18F-FDG PET/CT. The following PET parameters were calculated for both tumor and bone marrow: maximum standardized uptake value (SUVmax) at both time points (SUVmax early and SUVmax delayed), SUVmax increment (SUVinc), RI, and BLR. Patients were treated with R-CHOP regimen and response at end of treatment was assessed. Results The final analysis included 98 patients with complete remission. At a median follow-up of 22 months, 57 patients showed no relapse, 74 survived, and 24 died. The 2-year relapse-free survival (RFS) values for patients with higher and lower RI-bm were 20% and 65.1%, respectively (p < 0.001), and for patients with higher and lower BLR were 30.2% and 69.6%, respectively (p < 0.001). The 2-year overall survival (OS) values for patients with higher and lower RI-bm were 60% and 76.3%, respectively (p = 0.023), and for patients with higher and lower BLR were 57.3% and 78.6%, respectively (p = 0.035). Univariate analysis revealed that RI-bm and BLR were independent significant prognostic factors for both RFS and OS (hazard ratio [HR] = 4.02, p < 0.001, and HR = 3.23, p < 0.001, respectively) and (HR = 2.83, p = 0.030 and HR = 2.38, p = 0.041, respectively). Conclusion Baseline RI-bm and BLR were strong independent prognostic factors in DLBCL patients. Clinical relevance statement Bone marrow retention index (RI-bm) and bone marrow-to-liver ratio (BLR) could represent suitable and noninvasive positron emission tomography/computed tomography (PET/CT) parameters for predicting pretreatment risk in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. Key Points • Bone marrow retention index (RI-bm) and bone marrow-to-liver ratio (BLR) are powerful prognostic variables in diffuse large B-cell lymphoma (DLBCL) patients. • High BLR and RI-bm are significantly associated with poor overall survival (OS) and relapse-free survival (RFS). • RI-bm and BLR represent suitable and noninvasive risk indicators in DLBCL patients. | ||
| 650 | 4 | |a Lymphoma, Large B-cell, Diffuse |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fluorodeoxyglucose F18 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rituximab, Prognosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prospective studies |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Basha, Mohammad Abd Alkhalik |0 (orcid)0000-0002-9075-8020 |4 aut | |
| 700 | 1 | |a Almalki, Yassir Edrees |4 aut | |
| 700 | 1 | |a Abdelmaksoud, Bader |4 aut | |
| 700 | 1 | |a Hefzi, Nabila |4 aut | |
| 700 | 1 | |a Alnagar, Ahmed A. |4 aut | |
| 700 | 1 | |a Mahdey, Sheren |4 aut | |
| 700 | 1 | |a Ali, Ismail Mohamed |4 aut | |
| 700 | 1 | |a Nasr, Ibrahim |4 aut | |
| 700 | 1 | |a Abdalla, Ahmed A. El-Hamid M. |4 aut | |
| 700 | 1 | |a Yousef, Hala Y. |4 aut | |
| 700 | 1 | |a Zaitoun, Mohamed M. A. |4 aut | |
| 700 | 1 | |a Elsayed, Saeed Bakry |4 aut | |
| 700 | 1 | |a Nada, Mohamad Gamal |4 aut | |
| 700 | 1 | |a Amin, Mohamed I. |4 aut | |
| 700 | 1 | |a Hassan, Rania Mostafa |4 aut | |
| 700 | 1 | |a Ali, Susan Adil |4 aut | |
| 700 | 1 | |a Dawoud, Tamer Mahmoud |4 aut | |
| 700 | 1 | |a Aly, Sameh Abdelaziz |4 aut | |
| 700 | 1 | |a Algazzar, Youssef H. |4 aut | |
| 700 | 1 | |a Abdelhamed, Heba |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European radiology |d Springer Berlin Heidelberg, 1991 |g 34(2023), 4 vom: 09. Okt., Seite 2500-2511 |w (DE-627)SPR00395112X |w (DE-600)1472718-3 |x 1432-1084 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:4 |g day:09 |g month:10 |g pages:2500-2511 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00330-023-10150-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.64 |q VZ |
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 4 |b 09 |c 10 |h 2500-2511 | ||